Albert David Ltd (ALBERTDAVD)
🎯 Key Takeaways
- Albert David Ltd is a mature, low-growth pharmaceutical company operating in a niche segment with stable but flat financial performance. The business shows no signs of expansion or strategic transformation, maintaining consistent promoter ownership while exhibiting minimal institutional investor presence.
- Revenue grew 18% QoQ to ₹101 in Q1FY27.
- ⚠️ 1) Persistent quarterly earnings volatility with no clear upward trend in profitability raises concerns about operational stability. 2) The CARE ratin
- Market Cap
- ₹501
- P/E Ratio
- 22.2
- P/B Ratio
- 1.28
- ROE
- 5.8%
- ROCE
- 7.3%
- Debt/Equity
- 0.07
- Div Yield
- 0.57%
- Promoter
- 62.2%
📖 The Story
Albert David Ltd is a mature, low-growth pharmaceutical company operating in a niche segment with stable but flat financial performance. The business shows no signs of expansion or strategic transformation, maintaining consistent promoter ownership while exhibiting minimal institutional investor presence. Financial results indicate cyclical profitability with recurring quarterly losses offset by periodic gains, suggesting operational volatility rather than structural growth.
📰 What's Happening
The company has recently completed its 87th Annual General Meeting where all shareholder resolutions were approved without material changes to capital plans or dividend policy. The board reviewed and approved unaudited Q1 FY27 results showing revenue of ₹101 crore and operating profit of ₹8 crore, though no forward-looking guidance or strategic initiatives were disclosed. A credit rating downgrade by CARE Ratings in June 2026 highlighted weakened financial performance, particularly impacting long-term facility ratings to CARE A with a Negative outlook. There have been no new capital expenditures, M&A announcements, or business diversification efforts disclosed in recent filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 87 | 90 | 86 | 101 |
| Operating Profit | 0 | 8 | 0 | 8 |
| OPM % | 0.4% | 9.3% | 0.0% | 8.2% |
| Net Profit | -3 | 15 | -21 | 32 |
| EPS | ₹-5.79 | ₹26.81 | ₹-37.56 | ₹56.07 |
Quarterly revenue has remained relatively flat between ₹86–101 crore over the past four quarters, with operating profitability showing significant volatility — swinging from ₹0 operating profit in Q4 FY26 to ₹8 crore in Q1 FY27. Operating margins fluctuated between 0% and 9.3%, reflecting inconsistent cost control or volume-driven profitability. Net profit turned positive in December 2025 (₹15 crore) and March 2026 (₹32 crore) after a loss of ₹21 crore in March 2026, but annualized figures suggest earnings remain highly episodic rather than trending upward. The absence of sustained margin expansion or revenue growth indicates operational performance is not improving structurally.
🔮 Management Outlook & What's Next
Management has not provided any forward-looking guidance, strategic roadmap, or commentary on future growth prospects in the recent board meeting filings or AGM outcomes. The disclosures are strictly procedural, focusing on compliance with regulatory requirements rather than business outlook or capital allocation plans. No new initiatives, product launches, or market expansions were communicated during the reporting period, leaving investor expectations without directional clarity from the management team.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 |
| Reserves | 387 | 408 | 386 | 388 |
| Borrowings | 12 | 4 | 28 | 41 |
| Total Liabilities | 511 | 535 | 519 | 533 |
| Fixed Assets | 98 | 82 | 100 | 94 |
| Investments | 260 | 296 | 243 | 277 |
| Total Assets | 511 | 535 | 519 | 533 |
The balance sheet shows minimal leverage with borrowings remaining low and stable at ₹28–41 crore over the past two fiscal years, while equity and reserves have slightly increased, indicating no aggressive deleveraging or capital return activity. Total assets have grown modestly from ₹511 crore to ₹533 crore, primarily driven by reserve accumulation rather than capital investment. There is no evidence of large-scale capex or strategic reinvestment, suggesting capital allocation is conservative and focused on maintaining financial stability rather than funding growth.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | -8 |
| Investing | -4 |
| Financing | +12 |
| Net Cash Flow | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 62.2% | 62.2% | 62.2% | 62.2% |
| FII | 0.6% | 0.6% | 0.6% | 0.6% |
| DII | 1.7% | 1.6% | 1.6% | 1.6% |
| Public | 27.7% | 27.4% | 27.4% | 28.1% |
| # Shareholders | 14,666 | 13,967 | 13,555 | 13,155 |
Promoter holding remains stable at 62.24% over the past year, indicating confidence or lack of exit intent, while institutional ownership (FII and DII) is extremely low at under 1% combined, suggesting limited investor interest or coverage. The number of public shareholders has gradually declined from 14,666 to 13,155, which may reflect retail consolidation but does not signal growing market confidence. There are no signs of activist activity or significant stakebuilding by large investors.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent quarterly earnings volatility with no clear upward trend in profitability raises concerns about operational stability. 2) The CARE rating downgrade with a Negative outlook signals deteriorating creditworthiness despite low leverage, pointing to underlying performance or cash flow weaknesses. 3) Absence of management guidance or strategic updates creates uncertainty around future growth drivers. 4) Low institutional and declining public shareholder participation may limit liquidity and increase price volatility.
📋 Recent Filings
- Announcement2026-09-22Albert David Ltd announced that its trading window will close on October 1, 2026, as required by SEBI insider trading rules, freezing insiders' PANs u…
- 🟡 Board Meeting2026-08-29Albert David Ltd held its 87th Annual General Meeting on 6 August 2026 via video conferencing, confirming shareholder approval of all resolutions incl…
- 🟡 Board Meeting2026-08-06Albert David Limited announced the outcome of its board meeting held on August 6, 2026, where the unaudited financial results for the quarter ended Ju…
- Announcement2026-07-04Albert David Limited announced the resignation of Cluster-Head Mr. Saikath Banerjee effective July 4, 2026, as required under SEBI LODR Regulation 30.…
- 🟡 Board Meeting2026-07-04No summary available
- share transfer2026-07-04Albert David Limited received a compliance certificate from its share transfer agent covering the period April 1 to June 30, 2026, confirming adherenc…
- 🔴 Announcement2026-06-26Albert David Limited received a credit rating downgrade from CARE Ratings on its bank facilities, reducing long-term facilities to ₹50.50 crores and l…
- Financial Results2026-06-23Albert David Limited announced that its trading window will close on 1 July 2026 in compliance with SEBI insider trading regulations, restricting desi…
- unitholding pattern2026-06-19The board approved the appointment of Amit Mahla as an additional director effective June 19, 2026, and as a whole-time director and CEO for five year…
- 🟡 Board Meeting2026-05-30No summary available
🧠 Analyst's Read
Albert David Ltd appears to be a cash flow-constrained, low-institutional-owned pharmaceutical company with flat financial performance and no visible catalysts. Investors should monitor for any shift in management commentary, capital allocation decisions, or improvement in credit metrics that might signal a turnaround, but currently lack forward momentum or strategic clarity.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ALBERTDAVD files new disclosures
Track ALBERTDAVD filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ALBERTDAVD — FreeFree account · 2 AI queries/day